Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on KalVista Pharmaceuticals with a $37.00 price target, citing positive developments in its competitive landscape and market growth potential. The RAPIDe-3 trial data alleviated concerns about IR deucrictibant's efficacy, enhancing KalVista's market position. Ekterly's efficacy is comparable to IR deucrictibant, suggesting strong market potential. Needham also maintained a Buy rating with a $28.00 target. Chatterjee is a 5-star analyst with a 30.8% average return.
Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on KalVista Pharmaceuticals and keeping the price target at $37.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on several factors, including the recent developments in KalVista Pharmaceuticals’ competitive landscape. The positive data from PHVS’ RAPIDe-3 trial, although initially perceived as a competitive threat, has actually alleviated concerns about the efficacy of IR deucrictibant, which had been a significant overhang on KALV’s stock.
Furthermore, the survey conducted among key opinion leaders indicates that the efficacy of KalVista’s Ekterly is comparable to that of IR deucrictibant, suggesting a strong competitive position in the market. The anticipation of continued rapid growth and the potential for Ekterly to capture a substantial share of the on-demand market by 2026 also contribute to the Buy rating. These factors collectively support the optimistic outlook for KalVista Pharmaceuticals’ stock performance.
According to TipRanks, Chatterjee is a 5-star analyst with an average return of 30.8% and a 63.54% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, KalVista Pharmaceuticals, and Opus Genetics.
In another report released today, Needham also maintained a Buy rating on the stock with a $28.00 price target.
